arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

PTC THERAPEUTICS, INC.

PTCT
$62.32 ▼ -3.60 (-5.46%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
59 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
91
Health
Excellent
Bullish
auto_awesome

Analytical Summary

PTC THERAPEUTICS, INC. shows strong fundamentals with top-quartile Profit Margin (%) and Operating Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $5.2B
Dividend Yield —
Revenue Growth 101.5% ↗
Op. Margin 41.3% ↗
ROIC 34.5% ↗
FCF / Share $1.53 ↗
Trailing P/E 61.7x
Price / Book —
FCF Yield 2.5%
Debt / Equity -3.24
info Valuation on last close. End-of-day price, Sep 23, 2026.

59-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$360.52M
↑ +101.5% —
Net Income Profit after all expenses
$83.50M
↑ +3072.4% —
Operating Margin Operating profit as % of sales
41.3%
↑ +150.5% 97th
FCF / Share Free cash flow per share
$1.53
↑ +309.5% —
Long-Term Debt Long-term obligations
$535.52M
↑ +87.2% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
97
Financial Health
96
Cash Quality ↑
67

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 16 years · 59 quarters